Nucleai and Debiopharm team up for cancer drug development

By The Science Advisory Board staff writers

January 14, 2021 -- Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per a new research collaboration.

Developed with pathology datasets and machine-learning methods, the Nucleai platform may be used to help identify biomarkers for response.

The biomarkers allow further stratification of patient populations between responders and nonresponders, improve the success rate of clinical trials, and shorten time-to-market for pharmaceutical treatments, the companies said in a statement.

The research agreement includes an undisclosed upfront payment to Nucleai and milestone payments related to progress in clinical studies and development of companion diagnostics.

How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion....
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel...
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter